Axsome Therapeutics (NASDAQ:AXSM) Given New $190.00 Price Target at HC Wainwright

Axsome Therapeutics (NASDAQ:AXSM) had its target price upped by analysts at HC Wainwright from $180.00 to $190.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 74.55% from the stock’s current price.

Several other research analysts have also recently commented on AXSM. Truist Financial boosted their price target on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Mizuho dropped their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, December 31st. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. Finally, Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $132.08.

Axsome Therapeutics Stock Up 3.5 %

NASDAQ AXSM opened at $108.85 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $111.51. The business has a 50 day moving average price of $93.41 and a two-hundred day moving average price of $90.64. The stock has a market cap of $5.27 billion, a PE ratio of -16.67 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same period in the prior year, the firm earned ($1.32) earnings per share. As a group, sell-side analysts predict that Axsome Therapeutics will post -4.72 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AXSM. JPMorgan Chase & Co. grew its stake in Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after buying an additional 27,534 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Axsome Therapeutics during the third quarter valued at $1,052,000. Pallas Capital Advisors LLC bought a new position in shares of Axsome Therapeutics during the fourth quarter worth about $2,237,000. Captrust Financial Advisors acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter worth about $514,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Axsome Therapeutics by 71.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock worth $1,234,000 after acquiring an additional 5,737 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.